Metastatic Uterine Cancer: What to Ask

Uterine cancer is an umbrella term. Two diseases sit under it.

One is endometrial carcinoma. It starts in the lining of the womb. The other is uterine sarcoma. It starts in muscle or in supporting tissue.

They are not treated with the same drugs. So the first question is which one you have, and who confirmed it.

NCI puts a number on it. Uterine sarcoma makes up less than 1 percent of all cancers of the female organs. It makes up 2 to 5 percent of cancers of the uterus.

NCI then splits that small group. Carcinosarcoma is 40 to 50 percent of it. Leiomyosarcoma is 30 percent. Sarcoma that starts in the lining tissue is 15 percent.

Ask which of those words is on your report.

NCI's patient summary covers stage III, stage IV and recurrent endometrial cancer. It lists surgery followed by chemotherapy and/or radiation. For people who cannot have surgery, it lists chemotherapy with internal and external radiation. For people who cannot have surgery or radiation, it lists hormone therapy. It also lists targeted therapy. That means an mTOR inhibitor, either everolimus or ridaforolimus, or the monoclonal antibody bevacizumab. A clinical trial is on the list too.

Immunotherapy is covered in NCI's health professional summary rather than that list. Two trials sit behind it. In Study 309/KEYNOTE-775, pembrolizumab and lenvatinib were tested after a platinum-based regimen stopped working. In RUBY, dostarlimab was added to chemotherapy.

The gain in RUBY was largest where mismatch repair was deficient. Mismatch repair is a lab test on the tumor. NCI reports a 36 percent lower risk of progression or death in the whole group. In the dMMR group, the risk was 72 percent lower. Both trials sorted women by that same test. Ask whether yours has been done.

Be ready for a blunt sentence. NCI's uterine sarcoma summary states there is currently no standard therapy for stage IV disease, and that these patients should enrol in a clinical trial. We are quoting that rather than softening it. Read "no standard therapy" as meaning no single agreed regimen, not that nothing is done: treatment is still given, and it is chosen for the exact subtype by a sarcoma specialist.

NCI does report which drugs have shown activity, and by subtype the figures diverge sharply. Ifosfamide shrank about 32 percent of carcinosarcomas, 33 percent of stromal sarcomas and 17 percent of leiomyosarcomas. Gemcitabine with docetaxel had a 53 percent response rate in leiomyosarcoma that could not be removed by surgery.

Those are response rates from particular studies, not survival, and not a running order for your treatment. The point to take from them is that the subtype on your pathology report drives everything here, which is why expert review of the slides comes before any drug conversation.

NCI also reports what fails. Cisplatin does not work in leiomyosarcoma, first line or second. Adding other drugs to doxorubicin is no better than doxorubicin alone.

Two specialties are involved here. A gynecologic cancer surgeon and a sarcoma specialist do not always see the same options.

Ask whether your case went to a tumor board. Ask whether a pathologist who focuses on this tissue reviewed the slides.

• Is this a carcinoma or a sarcoma, and who confirmed it?
• Which subtype is on my report?
• Has my tumor been tested for mismatch repair?
• Does immunotherapy apply to me?
• If it is a sarcoma, which drugs have real activity in my subtype?
• Which trial should I look at now?
• Should a sarcoma specialist see my case too?

Metastatic uterine cancer raises the risk of blood clots, of the bowel becoming blocked, and of heavy bleeding. Each has a different level of urgency.

• Call 911 or go to an emergency department if you have chest pain, sudden trouble breathing, coughing up blood, or you faint. In someone with a clot in the leg, these can mean the clot has moved to the lungs.
• Call 911 or go to an emergency department if vaginal bleeding is very heavy, or comes with dizziness or feeling faint.
• Call your care team the same day if you have a swollen abdomen that does not settle, repeated vomiting, or you cannot pass stool or gas. Together these suggest the bowel is blocked, which can happen when disease sits in the abdomen.
• Contact your oncology team straight away, whatever the hour, if you have a temperature of 100.4°F (38°C) or higher while on chemotherapy. With white cell counts low, an infection can spread within hours, so this is a medical emergency and not something to leave until morning. If no one answers quickly, go to an emergency department and tell them you are on chemotherapy.
• Call your care team within a day or two if one leg becomes swollen, painful, warm, or red. That is the usual picture of a clot in a deep vein.
• Call your care team within a day or two if bleeding is lighter but new, or pelvic or back pain is steadily getting worse.

Cancer Staging and Biomarker Testing explain the terms behind a metastatic uterine cancer diagnosis. Three more pages cover the choices that come next. They are Clinical Trial vs Standard Treatment, Palliative Care, and Questions to Ask Your Doctor.

These questions were drawn from current patient guidance for uterine cancer:

• NCI PDQ — Uterine Sarcoma Treatment (Patient Version)
• NCI PDQ — Uterine Sarcoma Treatment (Health Professional Version)
• NCI PDQ — Endometrial Cancer Treatment (Patient Version)
• NCI PDQ — Endometrial Cancer Treatment (Health Professional Version)
• NCI — Drugs Approved for Endometrial Cancer
• MedlinePlus — Deep vein thrombosis, accessed August 11, 2026
• MedlinePlus — Intestinal obstruction, accessed August 11, 2026
• MedlinePlus — Vaginal bleeding, accessed August 11, 2026
• StatPearls (NCBI Bookshelf) — Neutropenic Fever, accessed August 11, 2026